Dermatitis, Irritant

Dermatologist shines a light on the latest research in photocontact dermatitis SAN DIEGO, March 8, 2024 /PRNewswire/ -- Sun sensitivity and related skin conditions are often misunderstood. Foods, medications, and skincare products can trigger symptoms like itching, redness, blistering, or burning. One of the most common conditions is photocontact dermatitis, a skin reaction occurring when certain substances come into contact with skin that is exposed to the sun. "Sun sensitivity is a common condition that can negatively impact a person's quality of life," said board-certified dermatologist Brandon Adler, MD, FAAD, an assistant professor of dermatology at Keck School of Medicine at the University of Southern California in Los Angeles, speaking at the American Academy of Dermatology's 2024 Annual Meeting. For many people, sun sensitivity is caused by the things they come into contact with, said Dr. Adler. If you develop rashes, blisters, or skin darkening after making a margarita or chopping vegetables for a salad, some of the ingredients may be to blame, said Dr. Adler. Your skin reaction could be caused by handling fruits and vegetables such as lime, figs and celery, or coming into contact with plants like hogweed and St. John's wort. Certain pain relief medications that are applied to the skin may also cause a photosensitive reaction, as can medications taken by mouth, such as some blood pressure medications like hydrochlorothiazide. While medications applied directly to the skin only cause a rash in the area of the body where it was applied, if a medication taken by mouth causes photosensitivity, it can cause a rash over any part of the body that was not protected from the sun. Reactions often appear as an itchy rash or severe sunburn on areas of the body most exposed to the sun, such as the face, neck, arms, or legs, according to Dr. Adler. To determine the cause of sun sensitivity reactions, dermatologists must consider a variety of individual factors, such as various product exposures and medical history, and less frequently bloodwork or a biopsy of the affected area of the skin. "While we will often prescribe anti-inflammatory medications to treat photocontact dermatitis, the primary treatment is identifying and avoiding the irritant or allergen," said Dr. Adler. "In many cases these are reversible reactions, so if the patient stops using the substance causing the reaction, then they will stop having symptoms and won't need ongoing treatment." Many people incorrectly assume that certain types of sun sensitivity only affect older people with lighter skin types, but recent research indicates that younger people and those with darker skin types are more susceptible than previously believed, according to Dr. Adler. New studies suggest that people with darker skin types are susceptible to two other types of photosensitivity, he said. The first is polymorphous light eruption (PMLE), which appears as tiny bumps or rashes that come and go with sun exposure. The second is chronic actinic dermatitis, which causes year-round rashes affecting the sun-exposed parts of the body due to light sensitivity. The exact causes of PMLE and chronic actinic dermatitis are not fully understood, but they are believed to involve an abnormal immune response to sunlight. While it is important for everyone to protect themselves from the sun, Dr. Adler noted that those with sun sensitivity need to be particularly mindful to seek shade, wear sun-protective clothing, and apply a broad-spectrum, water-resistant sunscreen with an SPF of 30 or higher. "If you notice a rash or blistering on your body after being in the sun, it's important to see a board-certified dermatologist, who can determine whether you have a sun-related skin disorder," said Dr. Adler. "No two patients are the same. A board-certified dermatologist can determine what is causing your sun sensitivity and provide a treatment option that works best for your condition." To find a board-certified dermatologist in your area, visit aad.org/findaderm. More Information Eczema Types: Contact Dermatitis Causes AAD B-Roll Library About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 20,800 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, TikTok, Pinterest and YouTube and @AADskin1 on Instagram. SOURCE American Academy of Dermatology

40,000 American Shoppers Voted Boudreaux's Butt Barrier® Ointment as Most Innovative Product of 2024 in Baby Care TARRYTOWN, N.Y., Feb. 9, 2024 /PRNewswire/ -- Boudreaux's Butt Paste's Butt Barrier® Ointment has been honored as a recipient of the prestigious 2024 Product of the Year USA Award, recognized as the top product in the baby care category based on a survey of 40,000 people by Kantar. The Product of the Year USA Award is one of the most respected honors in the consumer goods industry, celebrating excellence in product innovation and quality. Boudreaux's Butt Barrier® Ointment stood out among a competitive field of products, showcasing its effectiveness in preventing diaper rash while maintaining the highest standards of safety and reliability. Continue Reading Product of the Year Logo Developed with the utmost care and expertise by Boudreaux's Butt Paste's team of experts, Boudreaux's Butt Barrier® Ointment offers a unique blend of ingredients designed to create a protective barrier against wetness and irritation. The Butt Barrier® Ointment is clinically tested, hypoallergenic, fragrance free and has been accepted by the National Eczema Association. Its gentle yet effective formula is safe for use at every diaper change providing peace of mind for parents, ensuring their little ones stay comfortable and happy. Recommended by pediatricians and trusted by parents, Boudreaux's Butt Paste® is relied upon to soothe and alleviate diaper rash discomfort and has been a staple for parents for over 40 years. "As we celebrate this remarkable achievement, we remain committed to our mission of helping parents care for their little ones with confidence and peace of mind," said Tim Crowley, Associate Director of Pediatrics at Prestige Brands. "This recognition is a testament to our dedication to providing parents with the best possible solutions for their baby's delicate skin. We are immensely grateful to our customers for their trust and support." As a globally recognized symbol of endorsement, Product of the Year has been active in the United States for 16 years and boasts over 30 years of operation worldwide. Serving as a reliable guide for shoppers, it aids in navigating the plethora of new products available, both online and in-store. In an era where consumers are increasingly mindful of their budgets and make discerning choices, the Product of the Year red seal serves as a distinctive marker. This mark assists consumers in identifying the most exceptional new products that excel in areas such as thoughtful design, quality, and innovation, cutting through the clutter on store shelves. For further information about Boudreaux's Butt Paste®, visit buttpaste.com. Additional details on the full list of 2024 Product of the Year Winners can be found at productoftheyearusa.com, along with on Instagram, Facebook and X (formerly Twitter) at #POYUSA2024. About Boudreaux's Butt Paste® Created by pharmacist and father of four, George Boudreaux, in 1978, Boudreaux's Butt Paste ® was born from the need for an effective and safe solution to treat diaper rash. Created specifically for parents who don't want to settle for anything less than the best, it uses a combination of efficacious ingredients to be fast acting without being harsh on a baby's skin. Boudreaux's Butt Paste ® is formulated without harmful ingredients and is free-from dyes, parabens, preservatives, and talc. Parents rely on this trusted and pediatrician-recommend diaper rash line to help soothe and relieve rash discomfort from the first use and beyond. Boudreaux's ® is part of C.B. Fleet Company, Incorporated, a Prestige Brands Company. About Product of the Year Product of the Year is the largest consumer-voted award for product innovation. Established over 30 years ago, POY currently operates in over 40 countries with the same purpose: Guide consumers to the best products in their market and reward manufacturers for quality and innovation. Product of the Year winners are backed by the votes of 40,000 consumers in a national representative study conducted by research partner Kantar, a global leader in consumer research. The award is a powerful merchandising program for marketers proven to increase product sales, distribution, and awareness. Winning products are announced in February each year and receive the right to use the Product of the Year logo in marketing communications for two years. For more information, visit productoftheyearusa.com. About Kantar Kantar is the world's leading marketing data, insight and consultancy company. We know more about how people live, feel, shop, vote, watch and post worldwide than any other company. Working across the entire sales and marketing lifecycle, we help brands uncover growth in an extraordinary world. Kantar is part of WPP and its services are employed by over half of the Fortune 500 companies in 100 countries. SOURCE Boudreaux's Butt Paste

CAMBRIDGE, England--( BUSINESS WIRE )--Napp Pharmaceuticals Limited, a member of the international network of Mundipharma independent associated companies, today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has authorised rezafungin for the treatment of invasive candidiasis in adults in Great Britain (GB). 1,2 The authorisation was based on positive results from the pivotal ReSTORE Phase III clinical trial which demonstrated statistical non-inferiority for rezafungin, dosed once weekly, when compared to the current standard of care, caspofungin, dosed once daily. 2,3,4 These findings are supported by the STRIVE Phase II clinical trial and an extensive nonclinical development program. 3,4 ReSTORE, a multicentre, prospective, randomised and double-blind Phase III trial compared the efficacy and safety of intravenous rezafungin with intravenous caspofungin in eligible patients with invasive candidiasis. 2,3 The primary efficacy outcome was global response (confirmed by the Data Review Committee [DRC]) at day 14. 3 Global response was determined from clinical response, mycological response, and radiologic response (for qualifying subjects with invasive candidiasis). 2,3 Of the 187 patients in the modified intention-to-treat (mITT) population, 59.1% of patients in the rezafungin group (55/93) and 60.6% of patients in the caspofungin group (57/94) had a global response of cure at day 14 (weighted treatment difference −1.1% [95% CI −14.9, 12.7]. 2,3 Non-inferiority was to be concluded if the lower bound of the 95% confidence internal (CI) for the difference in Day 14 cure rates (rezafungin – caspofungin) was >-20%. 2 Rezafungin was generally well tolerated in clinical trials, to date very common adverse reactions include hypokalaemia, pyrexia, and diarrhoea. Common adverse reactions include anaemia, hypomagnesaemia, hypophosphataemia, hypotension, wheezing, vomiting, nausea, abdominal pain, constipation, erythema, and rash. Increased blood alkaline phosphatase, hepatic enzymes, alanine aminotransferase, aspartate aminotransferase and blood bilirubin were also common. Uncommon adverse events were hyperphosphataemia, hyponatraemia, phototoxicity, tremor and increased eosinophil count. There were spontaneous reports of urticaria (frequency not known). Transient infusion-related reactions have occurred with rezafungin, characterised by flushing, sensation of warmth, nausea, and chest tightness. 2 Rezafungin may cause increased risk of phototoxicity. Eligible patients should be advised to avoid sun exposure and other sources of UV radiation without adequate protection during treatment and for 7 days after the last administration of rezafungin. 2 Invasive candidiasis , is a severe, life-threatening infection of the bloodstream and/or deep/visceral tissues. 10,11 It affects seriously ill people, especially those with a weakened immune system and the mortality rate can be 40% or more. 12,13 It can place a large burden on the healthcare system, with the potential for extended treatment regimens and long hospital stays. 14 In the last 15 years there have been no new treatments and morbidity and mortality rates remain largely the same, indicating the need for alternative treatment options. 5-9,15 Professor P. Lewis White PhD, FECMM, FRCPath, Consultant Clinical Scientist and Head of the PHW Mycology Reference Laboratory, Honorary Professor, Cardiff University Centre for Trials Research said “ Invasive candidiasis remains a difficult-to-treat disease which has a significant impact on critically ill and immunocompromised patients. With limited advances in treating this condition over the past 15 years, today’s announcement is a positive step towards supporting eligible patients and could enable the healthcare professional community an alternative way to manage these patients with invasive candidiasis using a new, once-weekly intravenous treatment option .” “ This authorisation is a culmination of years of developing an additional treatment option for eligible adult patients suffering from invasive candidiasis and underscores our commitment to supporting management of infectious diseases, ” said Dr Ben David, Medical Director for Northern Europe at Mundipharma. Rezafungin has been granted Orphan Drug Designation (ODD) in GB for the treatment of invasive candidiasis in adults. 1 The MHRA grants ODD to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 5 in 10,000 people in GB where no satisfactory method of diagnosis, prevention or treatment of the condition concerned exists, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. 16 *ENDS* About invasive candidiasis Invasive candidiasis (IC) continues to be an area of significant unmet need, especially for critically ill patients in hospitals and patients with compromised immune systems. 14 Despite a number of available treatments, the mortality rate for patients with invasive candidiasis can be 40% or more. 13,14 IC is characterised as a severe, life-threatening systemic Candida infection of the bloodstream and/or deep/visceral tissues. 17 About Rezafungin Rezafungin is a novel once-weekly echinocandin that has been developed for the treatment of invasive candidiasis in adults. 18 About Napp Napp Pharmaceuticals Limited is part of Mundipharma, a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America, and the Middle East. Mundipharma is dedicated to bringing innovative treatments to patients in the areas of pain management, infectious disease and consumer healthcare as well as other severe and debilitating disease areas. Our guiding principles, centered around Integrity and Patient-Centricity, are at the heart of everything we do. For more information visit www.mundipharma.com Future clinical trial data A second Phase III clinical trial of rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial) is currently being conducted. 18 Registered office addresses NAPP PHARMACEUTICALS LIMITED a company having its registered office at Cambridge Science Park, Milton Road, Cambridge CB4 0AB, England. MUNDIPHARMA RESEARCH LIMITED, a company having its registered office at Cambridge Science Park, Milton Road, Cambridge, CB4 0AB, England. ® REZZAYO is a Registered Trademark of Cidara Therapeutics, Inc, used under license. References 1. UK Medicines and Healthcare Products Regulatory Agency authorisation. Available at: https://www.gov.uk/government/news/rezzayo-approved-to-treat-adult-patients-with-invasive-candidiasis (last accessed February 2024) 2. REZZAYO ® Summary of Product Characteristics. 3. Thompson GR, et al. Lancet 2023;401(10370):49–59. 4. Thompson GR, et al. Lancet Infect Dis 2023; https://doi.org/10.1016/S1473-3099(23)00551-0 5. Ham YY, et al. Future Microbiology 2021;16(1):27–36. 6. CANCIDAS (formerly Caspofungin MSD) EPAR. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/cancidas-previously-caspofungin-msd (last accessed February 2024). 7. Vfend (voriconazole) EPAR. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/vfend (last accessed February 2024). 8. Ecalta (anidulafungin) EPAR. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/ecalta (last accessed February 2024). 9. Mycamine (micafungin) EPAR. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/mycamine (last accessed February 2024). 10. Pappas PG, et al. Nat Rev Dis Primers 2018;4:18026. 11. CDC. Invasive candidiasis. Available at: https://www.cdc.gov/fungal/diseases/candidiasis/invasive/definition.html (last accessed February 2024). 12. Kullberg BJ, Arendrup MC. N Engl J Med 2015;373:1445–56. 13. Bassetti M, et al. Crit Care 2019;23(1):219. 14. Cortegiani A, et al. Cochrane Database Syst Rev 2016;2016:Cd004920. 15. Bassetti M, et al. J Antimicrob Chemother 2018; 73 Suppl 1: i14–i25 doi:10.1093/jac/dkx445. 16. UK Medicines and Healthcare Products Regulatory Agency, Guidance – Orphan medicinal products. Available at: https://www.gov.uk/guidance/orphan-medicinal-products-in-great-britain (last accessed February 2024). 17. Cortes JA, Corrales IF. Invasive candidiasis: Epidemiology and Risk Factors. November 2018. Available at https://www.intechopen.com/chapters/64365 (last accessed February 2024). 18. Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of invasive candidiasis. Available at https://www.mundipharma.com/Cidara-Therapeutics-and-Mundipharma-Announce-Positive-Topline-Results-from-the-Global-Phase-3-Pivotal-ReSTORE-Trial-of-Rezafungin-for-the-Treatment-of-Candidemia-and-Invasive-Candidiasis (last accessed February 2024). Job code: UK-RZF-2300053 Date of preparation: February 2024